(Q45879180)

English

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/26362483

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/26362483

Steven R. Lentz

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Waldemar Tomczak

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

J N Mahlangu

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

K N Weldingh

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

S Kaicker

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

F A Karim

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

T Matsushita

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

M Recht

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

S Ehrenforth

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

K Knobe

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

adept™2 Investigators

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

12 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/26362483

Journal of Thrombosis and Haemostasis

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1989-1998

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Vatreptacog alfa from conception to clinical proof of concept.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

The origins of enhanced activity in factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Preclinical models used for immunogenicity prediction of therapeutic proteins

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

A large-scale computational study of inhibitor risk in non-severe haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.13141

21 January 2018

Identifiers

10.1111/JTH.13141

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26362483%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45879180&oldid=2088297898"